Cytophage Technologies Ltd. Stock

Equities

CYTO

CA2328211081

Pharmaceuticals

Delayed Toronto S.E. 03:56:26 2024-05-17 pm EDT 5-day change 1st Jan Change
0.51 CAD +10.87% Intraday chart for Cytophage Technologies Ltd. +41.67% -27.62%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2022 - Sales 2023 - Capitalization 16.05M 21.85M
Net income 2022 -3M -4.08M Net income 2023 -4M -5.45M EV / Sales 2022 -
Net cash position 2022 2.14M 2.91M Net Debt 2023 1.76M 2.39M EV / Sales 2023 -
P/E ratio 2022
-5.07 x
P/E ratio 2023
-6.45 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
Cytophage Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cytophage Technologies Ltd. Appoints Michael D. Cochrane as Newest Member of Board of Directors CI
Cytophage Technologies Ltd. Provides Update on Bacteriophage Human Trial at The Ottawa Hospital CI
Cytophage Technologies Ltd. Provides Update on Upcoming Product for Egg Production in Canada CI
Cytophage Technologies Inc. completed the acquisition of Cuspis Capital III Ltd. (TSXV:CIII.P) in a reverse merger transaction. CI
Cuspis Capital III Ltd. announced that it has received CAD 2.5 million in funding CI
Cuspis Capital III Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cytophage Technologies Ltd. announced that it expects to receive CAD 2.5 million in funding CI
Cuspis Capital III Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Cytophage Technologies Inc. entered into a letter of intent to acquire Cuspis Capital III Ltd. (TSXV:CIII.P) in a reverse merger transaction. CI
Cytophage Technologies Inc. announced that it expects to receive $5 million in funding from Cuspis Capital III Ltd. CI
Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Cuspis Capital III Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Cuspis Capital III Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 day+10.87%
1 week+41.67%
Current month+54.55%
1 month+25.93%
3 months+17.24%
6 months-27.62%
Current year-27.62%
More quotes
1 week
0.36
Extreme 0.36
0.52
1 month
0.31
Extreme 0.305
0.52
Current year
0.31
Extreme 0.305
0.76
1 year
0.31
Extreme 0.305
0.76
3 years
0.27
Extreme 0.2694
1.12
5 years
0.27
Extreme 0.2694
1.12
10 years
0.27
Extreme 0.2694
1.12
More quotes
Managers TitleAgeSince
Chief Executive Officer - Feb. 07
Director of Finance/CFO 49 Feb. 07
Chief Operating Officer - Feb. 07
Members of the board TitleAgeSince
Chairman 72 -
Director/Board Member - -
Chief Executive Officer - Feb. 07
More insiders
Date Price Change Volume
24-05-17 0.51 +10.87% 63,500
24-05-16 0.46 +12.20% 165,000
24-05-15 0.41 +3.80% 24,000
24-05-14 0.395 -1.25% 26,000
24-05-13 0.4 +11.11% 35,550

Delayed Quote Toronto S.E., May 17, 2024 at 03:56 pm EDT

More quotes
Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.
Calendar
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW